BCR-ABL-IN-5

Names

[ CAS No. ]:
1795736-60-5

[ Name ]:
BCR-ABL-IN-5

Biological Activity

[Description]:

BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl

[Target]

IC50: 6.5 μM (K562)[1].


[In Vitro]

BCR-ABL-IN-5 (compound II) (0-100 mM, 72 hours) can inhibit the proliferation of K562 human leukemia cells[1]. Cell Proliferation Assay[1] Cell Line: K562 human leukemia cell line Concentration: 0-100 μM Incubation Time: 72 hours Result: Inhibited K562 proliferation with an IC50 value of 6.5 μM.

[References]

[1]. Ashraf K El-Damasy, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem. 2020 Dec 1;207:112710.

Chemical & Physical Properties

[ Molecular Formula ]:
C25H21Cl2N5O2

[ Molecular Weight ]:
494.37

Related Compounds